1140
New Delhi, May 27
Zydus Cadila on Thursday said it is seeking permission from Drugs Controller General of India (DCGI) to initiate human clinical trials for monoclonal antibodies cocktail for treatment of Covid. Zydus is currently seeking permission to initiate phase 1/3 human clinical trials from the DCGI. ZRC-3308, a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild Covid, Cadila Healthcare said in a regulatory filing.
Cadila Healthcare is the listed entity of the group.
ZRC-3308 has been found to be safe and well tolerated in animal toxicology studies.
Zydus said it is the only Indian company to have developed a neutralizing monoclonal antibody-based cocktail for the treatment of Covid.
India's pharma major Zydus Cadila has said it is seeking permission from the Drugs Controller General of India (DCGI) to initiate human clinical trials for monoclonal antibodies cocktail which treats mild to moderate Covid-19. "Zydus is currently seeking permission to initiate phase 1/3 human clinical trials from the DCGI. ZRC-3308, a cocktail of two SARS-CoV-2-neutralizing
The second and much more lethal COVID-19 wave, which swept through India in April and early May, is believed to be abating as the number of people getting infected or.
Zydus Cadila seeks DCGI nod for human clinical trials of antibodies cocktail to treat COVID-19 yourstory.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yourstory.com Daily Mail and Mail on Sunday newspapers.
URL copied
Covid-19: Zydus seeks DCGI nod to undertake clinical trials for monoclonal antibodies cocktail
Zydus Cadila on Thursday said it is seeking permission from Drugs Controller General of India (DCGI) to initiate human clinical trials for monoclonal antibodies cocktail for treatment of COVID-19.
âZydus is currently seeking permission to initiate phase 1/3 human clinical trials from the DCGI⦠ZRC-3308, a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild COVID 19,â Cadila Healthcare said in a regulatory filing.
Cadila Healthcare is the listed entity of the group. ZRC-3308 has been found to be safe and well tolerated in animal toxicology studies.